These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 30016794)

  • 21. [Therapy of atrial fibrillation with class III anti-arrhythmia agents].
    Follath F; Candinas R; Frielingsdorf J
    Herz; 1993 Feb; 18(1):20-6. PubMed ID: 8454249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The utility of serum drug level monitoring during therapy with class III antiarrhythmic agents.
    Follath F
    J Cardiovasc Pharmacol; 1992; 20 Suppl 2():S41-3. PubMed ID: 1279308
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intrapericardial delivery of amiodarone and sotalol: atrial transmural drug distribution and electrophysiological effects.
    Bolderman RW; Hermans JJ; Rademakers LM; Jansen TS; Verheule S; van der Veen FH; Maessen JG
    J Cardiovasc Pharmacol; 2009 Oct; 54(4):355-63. PubMed ID: 19701096
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of a combination of class III and class Ic antiarrhythmic agents in patients with electrical storm.
    Fuchs T; Groysman R; Meilichov I
    Pharmacotherapy; 2008 Jan; 28(1):14-9. PubMed ID: 18154469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacodynamic, pharmacokinetic and antiarrhythmic properties of d-sotalol, the dextro-isomer of sotalol.
    Advani SV; Singh BN
    Drugs; 1995 May; 49(5):664-79. PubMed ID: 7601009
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Historical development of the concept of controlling cardiac arrhythmias by lengthening repolarization: particular reference to sotalol.
    Singh BN
    Am J Cardiol; 1990 Jan; 65(2):3A-11A; discussion 35A-36A. PubMed ID: 2403733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High defibrillation threshold at cardioverter defibrillator implantation under amiodarone treatment: favorable effects of D, L-sotalol.
    Boriani G; Biffi M; Frabetti L; Maraschi M; Branzi A
    Heart Lung; 2000; 29(6):412-6. PubMed ID: 11080321
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sotalol: Current Status and Expanding Indications.
    Singh BN
    J Cardiovasc Pharmacol Ther; 1999 Jan; 4(1):49-65. PubMed ID: 10684524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A prospective, randomized controlled trial comparing the efficacy and safety of sotalol, amiodarone, and digoxin for the reversion of new-onset atrial fibrillation.
    Joseph AP; Ward MR
    Ann Emerg Med; 2000 Jul; 36(1):1-9. PubMed ID: 10874228
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of intravenously administered amiodarone for short-term control of serious arrhythmias.
    Hohnloser SH; Zabel M; Zehender M; Meinertz T; Just H
    J Cardiovasc Pharmacol; 1992; 20 Suppl 2():S63-9. PubMed ID: 1279311
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Arrhythmia control by prolonging repolarization: the concept and its potential therapeutic impact.
    Singh BN
    Eur Heart J; 1993 Nov; 14 Suppl H():14-23. PubMed ID: 7904934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.
    Connolly SJ; Dorian P; Roberts RS; Gent M; Bailin S; Fain ES; Thorpe K; Champagne J; Talajic M; Coutu B; Gronefeld GC; Hohnloser SH;
    JAMA; 2006 Jan; 295(2):165-71. PubMed ID: 16403928
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pediatric Dosing of Intravenous Sotalol Based on Body Surface Area in Patients with Arrhythmia.
    Li X; Zhang Y; Liu H; Jiang H; Ge H; Zhang Y
    Pediatr Cardiol; 2017 Oct; 38(7):1450-1455. PubMed ID: 28755092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiarrhythmic effect of ranolazine in combination with class III drugs in an experimental whole-heart model of atrial fibrillation.
    Frommeyer G; Milberg P; Uphaus T; Kaiser D; Kaese S; Breithardt G; Eckardt L
    Cardiovasc Ther; 2013 Dec; 31(6):e63-71. PubMed ID: 23647657
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [New anti-arrhythmia agents].
    Honerjäger P; Schmidt G
    Z Kardiol; 1992; 81 Suppl 4():133-7. PubMed ID: 1363260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up.
    Lodziński P; Kiliszek M; Koźluk E; Piątkowska A; Balsam P; Kochanowski J; Scisło P; Piątkowski R; Opolski G
    Cardiol J; 2014; 21(4):384-91. PubMed ID: 24142681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sotalol: a new class III antiarrhythmic agent.
    Zanetti LA
    Clin Pharm; 1993 Dec; 12(12):883-91. PubMed ID: 8137605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sotalol.
    Ruffy R
    J Cardiovasc Electrophysiol; 1993 Feb; 4(1):81-98. PubMed ID: 8287239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concentration-dependent pharmacologic properties of sotalol.
    Wang T; Bergstrand RH; Thompson KA; Siddoway LA; Duff HJ; Woosley RL; Roden DM
    Am J Cardiol; 1986 May; 57(13):1160-5. PubMed ID: 3706170
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New antiarrhythmic drug in pediatric use: sotalol.
    Pfammatter JP; Paul T
    Pediatr Cardiol; 1997; 18(1):28-34. PubMed ID: 8960489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.